Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Analysis and visualization of epidemics on the timescale of burden: derivation and application of Epidemic Resistance Lines (ERLs) to COVID-19 outbreaks in the US

View ORCID ProfileAlex Washburne, View ORCID ProfileJustin Silverman, View ORCID ProfileJose Lourenco, View ORCID ProfileNathaniel Hupert
doi: https://doi.org/10.1101/2021.05.03.21256542
Alex Washburne
1Selva Analytics LLC, Bozeman, MT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alex Washburne
  • For correspondence: alex.d.washburne{at}gmail.com
Justin Silverman
2College of Information Science and Technology, Pennsylvania State University, University Park, PA, USA
3Department of Statistics, Pennsylvania State University, University Park, PA, USA
4Department of Medicine, Pennsylvania State University, University Park, PA, USA
5Institute for Computational and Data Science, Pennsylvania State University, University Park, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Justin Silverman
Jose Lourenco
6Department of Zoology, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jose Lourenco
Nathaniel Hupert
7Weill Cornell Medicine and Cornell Institute for Disease and Disaster Preparedness, New York, NY, USA
8The COVID-19 International Modeling (CoMo) Consortium, University of Oxford, Oxford UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nathaniel Hupert
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The 2020 COVID-19 pandemic produced thousands of well-quantified epidemics in counties, states, and countries around the world. Comparing the dynamics and outcomes of these nested epidemics could improve our understanding of the efficacy of non-pharmaceutical interventions (NPIs) and help managers with risk assessment across multiple geographic levels. However, cross-outbreak comparisons are challenging due to their variable dates of introduction of the SARS-CoV-2 virus, rates of transmission, case detection rates, and asynchronous and diverse management interventions.

Here, we present a graphical method for comparing ongoing COVID-19 epidemics by using disease burden as a natural timescale for comparison. Trajectories of growth rates of cases over the timescale of lagged deaths per-capita produces coherent visual comparisons of epidemics that are otherwise incoherent and asynchronous in the timescale of calendar dates or incomparable using non-stationary measures of burden such as cases. Applied to US COVID-19 outbreaks at the county and state level, this approach reveals lockdowns reducing transmission at fewer deaths per-capita early in the epidemic, reopenings causing resurgent summer epidemics, and peaks that while separated in time and place actually occur at points of similar per-capita deaths.

Our method uses early and minimally mitigated epidemics, like that in NYC in March-April 2020 and Sweden in later 2020, to define what we call “epidemic resistance lines” (ERLs) or hypothesized upper bounds of epidemic speed and burden. ERLs from less-mitigated epidemics allow benchmarking of resurgent summer epidemics in the US. In particular, the unmitigated NYC epidemic resistance line appears to bound the growth rates of 3,000 US counties and funnel growth rates across counties to their peaks where growth rates equal zero in the fall and winter of 2020. Corroboration of upper-bounds on epidemic trajectories allowed early predictions of mortality burden for unmitigated COVID-19 epidemics in these populations, predictions that were more accurate for counties in states without mask-wearing mandates. We discuss how this method could be used for future epidemics, including seasonal epidemics caused by influenza or ongoing epidemics caused by new SARS-CoV-2 variants.

Press Summary Why, despite no statewide mask-wearing mandates or other restrictions like restaurant closures, did South Dakota’s COVID-19 epidemic peak not in January, when seasonal forcing wanes, but in early November? Why are we not seeing a resurgent epidemic in Florida or Texas, where non-pharmaceutical interventions have been relaxed for months? How can we compare the current outbreak in India with other countries’ epidemics to contextualize the speed of the Indian outbreak and estimate the potential loss of life?

We have developed a new method of visualizing epidemics in progress that can help to compare distinct COVID-19 outbreaks to understand, in specific cases like South Dakota, why they peaked when they did. The “when” in this case does not refer to prediction of a calendar date, but rather a point in the accumulation of deaths in a given locale due to the disease in question. The method presented in this paper therefore essentially uses population-based burden of disease as a timescale for measuring epidemics. Just as the age of a car can be measured in years or miles, the age of a COVID-19 epidemic can be measured in days or deaths per-capita. Plotting growth rates of cases as a function of per-capita deaths 11 days later produces a real-time visual comparison of epidemics that are otherwise asynchronous in time.

This approach permits both direct comparison across local outbreaks that may be disparate in time and/or place, as well as benchmarking of any outbreak against known exemplars of archetypal response strategies, such as New York City’s unmitigated urban outbreak in Spring 2020 and Sweden’s uncontained summer 2020 epidemic. Whether comparing the speed of resurgent outbreaks following relaxation in US states like Florida or the peak mortality burden in fall outbreaks across thousands of US counties with and without statewide mask-wearing mandates, this method offers a simple, intuitive tool for real-time monitoring and prediction capability connecting epidemic speed, burden, and management interventions. While our findings point to compelling epidemiological hypotheses for peaks in less-regulated states, future work is needed to confirm and extend our results predicting mortality burden at the peak of confirmed cases in the ongoing and evolving COVID-19 pandemic.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No external funding was received for this work.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

N/A

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Added Nathaniel Hupert's OrcID number & updated affiliation "CoMo" to "The COVID-19 International Modeling (CoMo) Consortium".

Data Availability

Data are available online through the R package COVID19, and we make our scripts available at the github repo: reptalex/COVID_ERL

https://github.com/reptalex/COVID_ERL

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted May 06, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Analysis and visualization of epidemics on the timescale of burden: derivation and application of Epidemic Resistance Lines (ERLs) to COVID-19 outbreaks in the US
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Analysis and visualization of epidemics on the timescale of burden: derivation and application of Epidemic Resistance Lines (ERLs) to COVID-19 outbreaks in the US
Alex Washburne, Justin Silverman, Jose Lourenco, Nathaniel Hupert
medRxiv 2021.05.03.21256542; doi: https://doi.org/10.1101/2021.05.03.21256542
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Analysis and visualization of epidemics on the timescale of burden: derivation and application of Epidemic Resistance Lines (ERLs) to COVID-19 outbreaks in the US
Alex Washburne, Justin Silverman, Jose Lourenco, Nathaniel Hupert
medRxiv 2021.05.03.21256542; doi: https://doi.org/10.1101/2021.05.03.21256542

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (434)
  • Allergy and Immunology (760)
  • Anesthesia (222)
  • Cardiovascular Medicine (3316)
  • Dentistry and Oral Medicine (366)
  • Dermatology (282)
  • Emergency Medicine (480)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1175)
  • Epidemiology (13403)
  • Forensic Medicine (19)
  • Gastroenterology (900)
  • Genetic and Genomic Medicine (5182)
  • Geriatric Medicine (483)
  • Health Economics (786)
  • Health Informatics (3286)
  • Health Policy (1146)
  • Health Systems and Quality Improvement (1199)
  • Hematology (432)
  • HIV/AIDS (1024)
  • Infectious Diseases (except HIV/AIDS) (14657)
  • Intensive Care and Critical Care Medicine (917)
  • Medical Education (478)
  • Medical Ethics (128)
  • Nephrology (526)
  • Neurology (4957)
  • Nursing (263)
  • Nutrition (735)
  • Obstetrics and Gynecology (889)
  • Occupational and Environmental Health (797)
  • Oncology (2531)
  • Ophthalmology (730)
  • Orthopedics (284)
  • Otolaryngology (348)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (547)
  • Pediatrics (1308)
  • Pharmacology and Therapeutics (552)
  • Primary Care Research (559)
  • Psychiatry and Clinical Psychology (4225)
  • Public and Global Health (7526)
  • Radiology and Imaging (1717)
  • Rehabilitation Medicine and Physical Therapy (1022)
  • Respiratory Medicine (982)
  • Rheumatology (480)
  • Sexual and Reproductive Health (500)
  • Sports Medicine (425)
  • Surgery (551)
  • Toxicology (73)
  • Transplantation (237)
  • Urology (206)